Business Context and Reporting Period
This Form 8-K is a current report filed by DanDrit Biotech USA, Inc. (not Lunai Bioworks Inc.) on April 28, 2015. The filing addresses corporate governance changes, specifically the appointment of a new Chief Financial Officer and the resignation of the previous CFO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and employment terms.
Material Changes
- Appointment of CFO: The Board appointed Lone Degn as Chief Financial Officer, effective April 30, 2015.
- Resignation of CFO: Robert Wolfe resigned as CFO on April 28, 2015, on amicable terms.
- Compensation: Ms. Degn's employment agreement with the subsidiary DanDrit Biotech A/S stipulates a monthly salary of DKK 60,000, subject to annual review.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of material risks and contingencies. The document is limited to the disclosure of the executive transition and the terms of the new CFO's employment agreement.
Investor Verification Checklist
- Verify the correct registrant name is DanDrit Biotech USA, Inc., as the input metadata referenced "Lunai Bioworks Inc."
- Confirm the effective date of the CFO transition (April 30, 2015) against internal corporate records.
- Review the full text of the "Degn Employment Agreement" (Exhibit 10.1) for additional compensation details or restrictive covenants not summarized in this report.
- Check subsequent filings for the formal election of a permanent CFO if Ms. Degn's role remains interim.